

## PRESSURE BIOSCIENCES INC.

14 Norfolk Avenue  
South Easton, MA 02375  
(T) 508-230-1828  
(F) 508-230-1829  
[info@pressurebiosciences.com](mailto:info@pressurebiosciences.com)

Mr. Richard T. Schumacher, CEO, President  
Dr. Edmund Y. Ting, SVP of Engineering  
Dr. Alexander V. Lazarev, Chief Science Officer  
Mr. John B. Hollister, Director, Marketing & Sales  
Mr. Daniel J. Shea, CPA, Senior Advisor - Finance

---

## STOCK OVERVIEW

Symbol:	PBIO	Recent Close:	\$2.50 (as of 11/01/21)
Exchange:	OTCQB	52-Week Range:	\$1.29 - \$4.98
Shares OS <sup>1</sup> :	6.7M (24.4M FD)	Market Capitalization <sup>2</sup> :	\$17M (\$61M FD)
Float:	~5.3M	Fiscal Year End:	December 31
Revenue (TTM)	\$1.867M	Transfer Agent:	Computershare

---

## COMPANY OVERVIEW

**Pressure BioSciences, Inc. (OTCQB: PBIO)** is a leader in the development & sale of innovative, enabling, high pressure platform technology solutions for the life sciences and other industries worldwide. Our products/services are based on three patented, high-pressure platforms: (i) Pressure Cycling Technology ("PCT"), (ii) BaroFold Technology ("BaroFold"), and (iii) Ultra Shear Technology ("UST").

**The PCT Platform** uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., critical steps performed by hundreds of thousands of scientists worldwide, such as cell lysis and biomolecule extraction from tissue samples). Our primary focus is on making our recently released, GMP-compliant, next generation PCT-based Barocycler EXTREME instrument available globally to biopharmaceutical drug manufacturers for use in the design, development, characterization, and quality control of biotherapeutic drugs. The PCT Platform is also used in such areas as biomarker and target discovery, soil & plant biology, anti-bioterror, and forensics. We currently have over 300 PCT instrument systems placed in approximately 200 academic, government, pharmaceutical, and biotech research laboratories worldwide. There are over 120 independent publications highlighting the advantages of using the PCT Platform in scientific research studies, many from worldwide key opinion leaders.

**The BaroFold Platform** can be used to significantly improve the quality and production costs of protein biotherapeutics. It employs high pressure for the disaggregation and controlled refolding of proteins to their desired native structures at yields and efficiencies not achievable using existing technologies. The BaroFold Platform has been shown to remove protein aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy, safety, and cost for both new-drug entities and biosimilar (follow-on biologic) products. The BaroFold Platform can help companies to more efficiently and cost effectively create, accelerate development, and manufacture novel protein biotherapeutics and follow-on biologics, and perform critical rescue/rework on aggregated or misfolded products. It is scalable and practical for standard manufacturing processes. This unique technology platform can help protein-based biopharmaceutical companies create and manufacture high quality, novel protein biotherapeutics and lower the cost of existing formulations. Research and manufacturing licenses are available.

**The UST Platform** is based on the use of intense shear forces from ultra-high pressure (greater than 20,000 psi) valve discharge with precisely controlled temperatures. UST has been shown to turn hydrophobic (water-repelling) oil-based nutrients, therapeutics, or other active ingredients into stable, effectively water-soluble nanoemulsion formulations. Such formulations are expected to gain enormous success in many markets, including pharmaceuticals, nutraceuticals, (e.g., water soluble, medically important plant extracts, such as CBD-enriched plant oil), cosmeceuticals, as well as broad food & beverage, agriculture, and industrial opportunities (e.g., inks, paints, lubricants, etc.). We believe that UST has the potential to play a significant role in many commercially important areas, including (i) stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water), delivering superior-performing products in diverse applications, and (ii) the preparation of higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies, e.g., dairy products. The UST Platform is currently being licensed into initial applications and developed for commercialization.

---

## INVESTMENT HIGHLIGHTS

- PBI has Proven Core Technology with Multiple Applications (Over 350 Pressure Systems Installed Globally)
  - PBI has Three Novel, Enabling, Patented & Proprietary Pressure-based Platforms: PCT, BaroFold, & UST
  - PCT Platform Breaks Through Bottlenecks to Enable/Accelerate Discovery & QC in Drug Development
  - BaroFold Platform Improves Quality and Reduces Production Costs of Protein Drug Therapeutics through Disaggregation and Controlled Refolding
  - UST Platform Makes Safer, More Bioavailable, Highly Stable Nanoemulsions for Multiple Major Markets
  - Significant Worldwide Market Opportunities: PCT and BaroFold (BioPharma R&D and QC \$526B); UST (CBD \$44B; Cosmeceuticals \$805B; BioPharma Manufacturing \$900B; Food and Beverages \$5.65T)
- 

## 2021 KEY ANNOUNCEMENTS

- **September 30:** PBI reports its UST platform successfully transforms Neem Oil into a novel, highly potent nanoemulsion for more effective agrochemical applications
  - **September 29:** Company announced forward integration plans for Ultra Shear Technology (UST) demonstration and to manufacturing partnerships on U.S. east and west coasts.
  - **August 19:** PBI reports Q2 financial results, including a 127% growth in total revenue, 178% growth in instrument sales, 298% growth in UST/BaroFold services, and a concomitant 51% decrease in operating loss.
  - **August 18:** PBI expands on recent announcements (i) \$1M in orders for PBI Agrochem, (ii) growth plan and goals for 2<sup>nd</sup> half of 2021, and (iii) pending acquisition of eco-friendly assets at the August 18 Emerging Growth Investor Conference: [Pressure Biosciences, Inc. \(OTCQB: P BIO\) Emerging Growth Conference 14 - August 18, 2021](#).
  - **August 12:** PBI's new green, eco-friendly agrochem wholly owned subsidiary (PBI Agrochem) receives over \$1,000,000 in orders in first month of operations.
  - **August 5:** PBI unveils aggressive growth plan and goals for second half 2021; Company marches toward UST commercial release; up-listing, and profitability.
  - **July 21:** PBI's President & CEO Ric Schumacher spoke at the July 21<sup>st</sup> Emerging Growth Conference where he expanded on the recent UST platform breakthroughs and impending agrochem asset acquisition.
  - **July 21:** PBI announces major business expansion, establishing eco-friendly agrochemicals subsidiary and initiating plans to drive accretive 2021 revenue.
  - **July 13:** PBI's UST-enabled nanoemulsions soar past one-year stability goal; results open explosive growth potential for water-soluble CBD-infused beverages worldwide.
  - **July 1:** PBI reported its novel UST platform delivered breakthrough nanoemulsion processing for one of the world's most potent antioxidants – Astaxanthin.
  - **June 23:** PBI presented a corporate overview - including a discussion of its resurgent revenue growth in 2021, the potential impact of the anticipated commercial release of its revolutionary Ultra Shear Technology™ (UST™) platform by Q4 2021, and its impending acquisition of assets of a global, eco-friendly agrochemicals at the Emerging Growth Conference. [P BIO Talk: Emerging Growth 062321](#)
  - **May 19:** PBI reports resurgent growth in 1<sup>st</sup> Quarter 2021: total revenue up 121%, instrument sales up 235%, consumable sales up 81%, gross margins up (31-60%), and operating loss down 23%.
  - **May 13:** Pressure BioSciences awarded three additional patents for revolutionary Ultra Shear Technology (“UST”) platform: Japan, Australia, and China.
  - **April 14:** Pressure BioSciences finalizes plan to acquire global eco-friendly agrochemical supplier. Company expects acquisition to be accretive with sustained profitable revenue growth.
  - **March 15:** Pressure BioSciences discusses partnerships with Leica Microsystems (cancer diagnostics) and Ohio State University (food industry consortium) with the Stock Day Podcast.
  - **March 4:** Transformative impact of food industry consortium formed by Pressure BioSciences and Ohio State University discussed in showcase video from Emerging Technology Insider.
  - **February 24:** PBI and Ohio State University announce formation of a food industry consortium to advance commercialization of the Company's Ultra Shear Technology (UST) platform.
  - **February 8:** Company announces plans to acquire the assets of a global eco-friendly agrochemical supplier.
  - **January 20:** PBI targets revolution in effectiveness of therapeutics via improved drug delivery and dosing safety; announces collaboration with SinuSys Corp to improve and optimize their lead sinus health product candidate prior to Phase IIb trials.
- 

## BOARD OF DIRECTORS

- Mr. Jeffrey N. Peterson, Chairman
- Mr. Kevin A. Pollack, Esq.
- Mr. Vito Mangiardi
- Dr. Mickey Urdea
- Mr. Richard T. Schumacher

1. Shares Outstanding (as 11.01.21) – includes approximately 6.7M Common Shares (CS), 1.2M CS Equivalents (CSE) from outstanding stock options, 8.5M CSE from Preferred Stock Series D, G, H, J, K, AA, and 8.0M CSE from convertible loans on an as-converted basis.
2. Fully Diluted Market Capitalization is calculated using Common Stock OS and Common Equivalent Shares OS on a Fully Diluted basis.

***This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities.***